Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.57 |
| ▸ | PNMT | P11086 | 6/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL746109 | 1.00 | HTR2C (0.57) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| Hydrochloric Acid SCHEMBL1124555 | 0.98 | HTR2C (0.55) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| Hydrochloric Acid SCHEMBL31062521 | 0.98 | HTR2C (0.55) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| Formaldehyde SCHEMBL30554785 | 0.95 | PNMT (0.55) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| SCHEMBL8467911 | 0.93 | CD274 (0.59) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| SCHEMBL532484 | 0.93 | CD274 (0.59) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| Hydrochloric Acid SCHEMBL587493 | 0.91 | CD274 (0.58) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| SCHEMBL2913248 | 0.89 | KCNH2 (0.54) | HTR2CHTR2AHTR2BKCNH2RYR2 | |
| SCHEMBL225918 | 0.89 | HTR2C (0.60) | HTR2CHTR2AHTR2BADRA2AADRA2B | |
| SCHEMBL31317936 | 0.89 | HTR2C (0.60) | HTR2CHTR2AHTR2BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| CN-115403570-B | Mu-opioid receptor agonist, preparation method thereof and application thereof in medicine field | 上海华汇拓医药科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-115772156-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-114853730-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-4277902-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | Ontario Institute for Cancer Research (OICR) (CA) | 2023-11-22 | — | — | EP | disclosed |
| CN-112513029-B | Nitrogen-containing aryl phosphorus oxide derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116940565-A | Isoindolinone aminopyrimidine compounds as inhibitors of NUAK kinase, compositions and uses thereof | 安大略省癌症研究所(OICR) | 2023-10-24 | — | — | CN | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-112552290-B | Amido bond-containing phenylfuran-2-tetrahydroisoquinoline compound and preparation method and application thereof | 浙江工业大学 | 2022-10-11 | — | — | CN | disclosed |
| CN-114853730-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-109863145-B | Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | HTR2C 503/4885HTR2A 1205/4885HTR2B 1455/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | HTR2C 2907/4885HTR2A 2108/4885HTR2B 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.